

## Nicolai Lindgreen

Partner (Copenhagen)



Nicolai Lindgreen's primary field of expertise is patent, trademark and other IP litigation.

Over the course of 30 years, Nicolai has conducted a multitude of high-profile patent and trademark cases before Denmark's highest courts as well as Danish and international arbitration tribunals. His extensive international network enables him to draw on advice and assistance from leading national and foreign experts in their fields.

Nicolai's hands-on and results-oriented approach ensures that disputes are steered towards the solution that best meets the client's commercial objectives, while averting unnecessary litigation.

Nicolai represents Danish and international clients within all industries, and particularly within life science and healthcare. He combines unique insight into Danish and international IP law with a keen analytical sense and an innovative approach. He values an informal environment and the ability to advance and convey the client's case succinctly and persuasively.

---

Dir. +45 38 77 43 70  
Mob. +45 40 61 14 82  
[nl@kromannreumert.com](mailto:nl@kromannreumert.com)  
[LinkedIn](#)

Practice areas  
[Dispute Resolution](#)  
[IP](#)  
[Life Science](#)

Industries  
[Healthcare](#)

Nicolai is rated in Tier 1 for IP by Chambers, is recognized in the "Hall of Fame" for IP by Legal 500 and has several times been named a "Global Elite Thought Leader" by WWL.

## High-profile cases

Nicolai Lindgreen has advised in the following cases:

- Fresenius Kabi against Biogen (Adalimumab) (2021)
- Mikkel Rundin Ørsted et al. against Ørsted A/S et al. (family name vs. company name and trademark) (2020)
- Novozymes against DuPont (entitlement to patent applications) (2020)
- Novozymes against DuPont (Arrow declarations) (2020)
- Bayer against Ceva (Forceris) (2020)
- Teva against Mylan (Copemyl) (2019)
- Eli Lilly against Mylan (Tadalafil) (2019)
- Krka against AstraZeneca (Esomeprazol) (2018)
- Coloplast against Hollister (entitlement to patent application) (2018)
- Gilead against Accord (Truvada SPC) (2018)
- Coloplast against MBH (urinary catheters) (2017)
- Accord against AstraZeneca (Quetiapin) (2016)

## Ratings

Based on client testimonials, acknowledged rating organizations have most recently rated Nicolai in:

- [Chambers Europe](#), Band 1, 2024
- [Chambers Global](#), Band 1, 2024
- [Legal 500](#), Hall of Fame, 2024
- [Who's Who Legal](#), Global Elite Thought Leader

## Background

### Career

- Kromann Reumert, Partner, 2000
- Right of audience before the Danish Supreme Court, 1999
- Kromann Reumert, 1988-

### Education

- Master of Laws, Jesus College, Cambridge, 1995

- Admitted to practise law 1993
- Master of Laws (*cand. jur.*), University of Copenhagen, 1990

## Languages

- Danish
- English

## Activities

- President of the Danish Association for the Protection of Intellectual Property Rights and of the Danish AIPPI Group
- AIPPI Award of Merit 2011
- Assistant Reporter General of AIPPI 2004-2010
- Member of the European Patent Lawyers Association (EPLAW), LES, ECTA, AIPLA, INTA, the Danish Supreme Court Bar Association ("Foreningen Højesteretsskranken")

## Publications

- Patent Protection for Second Medical Uses, Wolters Kluwer, 2016, 2nd edition 2020
- Patentloven med kommentarer (The Annotated Danish Patents Act), 2nd edition 2018
- The Unitary Patent Court - Administration of Justice at the New European Patent Court (Den Fælles Patentdomstol - Retsplejen ved Europas nye patentdomstol), Karnov Publishers, 2015
- Concise European Trade Mark and Design Law, Kluwer Law International
- Danish chapter in Handbuch der Markenpiraterie in Europa, C.H. Beck
- Evidence by court-appointed experts and party-appointed experts in patent litigation (commemorating the 150th anniversary of the Danish Maritime and Commercial High Court) 2011